Beijing Ailijia Pharmaceutical Technology

Beijing Ailijia Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in Beijing, China, specializing in the development of innovative small molecule therapeutics for oncology and other serious diseases. The company's research strategy focuses on targeting specific signaling pathways and molecular drivers of cancer to create highly selective and potent drug candidates. Its lead program, ALJ-101, is a selective fibroblast growth factor receptor 4 (FGFR4) inhibitor currently undergoing clinical trials for the treatment of advanced hepatocellular carcinoma. Ailijia leverages its internal R&D expertise to advance a diverse pipeline of candidates from discovery through clinical proof-of-concept. Supported by leading venture capital investors, the company aims to deliver transformative medicines to patients with limited treatment options.